Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.32 |
| ▸ | TACR1 | P25103 | 4/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.31 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.31 |
| ▸ | RORA | P35398 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869923 | 0.94 | P2RX1 (0.36) | NR2E1TACR1P2RX1P2RX3P2RX4 | |
| SCHEMBL870518 | 0.91 | TACR1 (0.32) | TACR1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL10072341 | 0.91 | HPGD (0.31) | HPGD | |
| SCHEMBL10072325 | 0.89 | GPR52 (0.37) | — | |
| SCHEMBL10072327 | 0.89 | — | — | |
| SCHEMBL870231 | 0.87 | HPGD (0.32) | P2RX7HPGD | |
| SCHEMBL10072324 | 0.86 | TAS2R14 (0.39) | HDAC3HDAC1HDAC2HDAC6TAS2R14 | |
| SCHEMBL871534 | 0.86 | HPGD (0.31) | P2RX7HPGD | |
| SCHEMBL883221 | 0.86 | HPGD (0.31) | P2RX7HPGD | |
| SCHEMBL10072331 | 0.85 | CA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | HDAC3 1241/4885HDAC1 925/4885HDAC2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.